Genen­tech can­cer R&D vet Raphaël Rousseau jumps ship, joins Grit­stone

When you’re look­ing to break new ground and make a rep­u­ta­tion for your­self in can­cer R&D, one of the best places to raid tal­ent is the leg­endary biotech Genen­tech. And the per­son­al­ized can­cer vac­cine play­er Grit­stone On­col­o­gy helped prove that point again to­day with the re­cruit­ment of Genen­tech vet and long­time can­cer re­searcher Raphaël F. Rousseau as its new chief med­ical of­fi­cer.

Rousseau’s long re­sume in­cludes a stint as glob­al fran­chise head for pe­di­atrics in Genen­tech’s Prod­uct De­vel­op­ment On­col­o­gy di­vi­sion. He “man­aged a clin­i­cal team of physi­cians and sci­en­tists across sites as well as a cross-func­tion­al de­vel­op­ment and study man­age­ment team of more than 60 peo­ple across sev­er­al key func­tions, in­clud­ing clin­i­cal sci­ence, safe­ty, reg­u­la­to­ry, re­search, bio­mark­ers, clin­i­cal phar­ma­col­o­gy and op­er­a­tions,” adds his short-form bi­og­ra­phers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.